The investment was co-led by Unusual Ventures, Motive Partners, and Bain Capital Ventures to fuel international expansion and product development.
"High-potential companies struggle to cope with large volumes of international payments and there is a huge gap in the market — at one end you have inefficient local solutions; at the other, you have the tier-one global providers, inaccessible to all but the world’s biggest businesses. Businesses have no option but to stitch together a costly and complex patchwork of service providers and this is the pain point that Paytrix is stepping in to solve."
The Series A round was led by Conviction with participation from numerous strategic and venture capital investors.
"The response from businesses to the capabilities of synthetic data has been huge. Enabling our customers to access and actually use their data unlocks real commercial value. Hazy has been working in the generative AI field since our inception in 2017 and we are excited to see where the space goes. This funding will solidify our position as the leading synthetic data provider for enterprises to unlock value through their data and enable us to explore the greater potential of generative AI to produce real results for businesses, with no privacy limitations."
The funding round involves participation from existing shareholders and new investors to provide employee liquidity.
"Over the last 12 years, current and former employees of Stripes have helped build foundational economic infrastructure for millions of businesses around the world, and this transaction gives them the opportunity to access the value they've helped create. But the internet economy is still young, and the opportunities of the next 12 years will dwarf those of the recent past. There's so much to discover and to create. For us, it's now back to work."
The £5.1m financing values the personal data platform at £30m and includes backing from high-profile figures such as Chris Gayle.
"We believe Gener8 is the first company in the world to enable people to centralise their data into one location and earn from it. We’ve built something that, until now, has only been theoretical in the world of academia"
The Yorkshire-based medical technology company secured backing from Mercia and private investors to support production and international expansion.
"The Eventum team have done a massive amount of work in a short space of time in developing Quadsense and getting it approved for clinical use. We are now excited to start scaling up the team to commercialise the product, as well as bringing further innovations to the orthopaedics market."
